A5071552976- Cancer Immunotherapy and Biomarkers
- Immunotherapy and Immune Responses
- Bacillus and Francisella bacterial research
- Immune cells in cancer
- Yersinia bacterium, plague, ectoparasites research
- CAR-T cell therapy research
- Adenosine and Purinergic Signaling
- Pancreatic and Hepatic Oncology Research
- RNA Interference and Gene Delivery
- Advanced Drug Delivery Systems
- Immune Response and Inflammation
- Immune Cell Function and Interaction
- Inhalation and Respiratory Drug Delivery
- Vibrio bacteria research studies
- Cancer Research and Treatments
- SARS-CoV-2 and COVID-19 Research
- Hepatitis B Virus Studies
- Cytokine Signaling Pathways and Interactions
- Viral gastroenteritis research and epidemiology
- Bacteriophages and microbial interactions
- Pharmacological Effects of Natural Compounds
- Respiratory viral infections research
- Clostridium difficile and Clostridium perfringens research
- Plant-based Medicinal Research
- Virus-based gene therapy research
AstraZeneca (United Kingdom)
2021-2025
AstraZeneca (Brazil)
2025
AstraZeneca (United States)
2022
National Institute for Biological Standards and Control
2018
Pfizer (United States)
2011-2016
Defence Science and Technology Laboratory
2001-2012
Salisbury University
2002-2005
Aston University
1995-2001
Stimulation of protective immune responses against intracellular pathogens is difficult to achieve using non-replicating vaccines. BALB/c mice immunized by intramuscular injection with killed Francisella tularensis (live vaccine strain) adjuvanted preformed stimulating complexes admixed CpG, were protected when systemically challenged a highly virulent strain F. (Schu S4). Serum from was used probe whole proteome microarray in order identify immunodominant antigens. Eleven out the top 12...
Background/Objectives: Pancreatic ductal adenocarcinoma (PDAC), expecting to be the second leading cause of cancer deaths by 2030, resists immune checkpoint therapies due its immunosuppressive tumor microenvironment (TME). Leukemia inhibitory factor (LIF) is a key target in PDAC, promoting stemness, epithelial-mesenchymal transition (EMT), and therapy resistance. Phase 1 clinical trials showed anti-LIF safe but with limited efficacy, suggesting better outcomes when combined chemotherapy,...
Background: Standard of care therapies such as radiotherapy and chemotherapy have shown little efficacy against pancreatic ductal adenocarcinoma (PDAC). Immunotherapy is a newly emerging form treatment that has promise; however, toxic systemic effects resulted in limited use the clinic. Shifting from to local delivery cancer therapeutics reduces adverse increases response rates multiple malignancies. Importantly, tumor-targeted on distal tissues, bone marrow, not been thoroughly...
ABSTRACT Existing licensed anthrax vaccines are administered parenterally and require multiple doses to induce protective immunity. This requires trained personnel is not the optimum route for stimulating a mucosal immune response. Microencapsulation of vaccine antigens offers number advantages over traditional formulations, including stability without refrigeration potential utilizing less invasive routes administration. Recombinant antigen (rPA), dominant protection against infection, was...
Background Stereotactic body radiotherapy (SBRT) induces immunogenic cell death, leading to subsequent antitumor immune response that is in part counterbalanced by activation of evasive processes, for example, upregulation programmed death-ligand 1 (PD-L1) and adenosine generating enzyme, CD73. CD73 upregulated pancreatic ductal adenocarcinoma (PDAC) compared with normal tissue high expression PDACs associated increased tumor size, advanced stage, lymph node involvement, metastasis, PD-L1...
Pancreatic ductal adenocarcinoma (PDAC) has a very poor prognosis because of its high propensity to metastasize and immunosuppressive microenvironment. Using panel pancreatic cancer cell lines, three-dimensional (3D) invasion systems, microarray gene signatures, microfluidic devices, mouse models, intravital imaging, we demonstrate that ROCK-Myosin II activity in PDAC cells supports transcriptional program conferring amoeboid invasive traits vivo metastatic abilities. Moreover, find immune...
Intratracheal delivery of aerosolized monoclonal antibodies with specificity for Yersinia pestis LcrV and F1 antigens protected mice in a model pneumonic plague. These data support the utility inhaled as fast-acting postexposure treatment
Abstract Factors relating to the transfer of latex microspheres 0·87 μm mean diameter from gastrointestinal tract (GIT) circulation have been investigated. The rapidity appearance and number particles increased when volume water used as a suspending vehicle was increased. This probably due barrier cell integrity being compromised so that movement across enterocytes would be enhanced. Particles were swept into these channels by waterflow. tonicity fluid important isotonic hypertonic saline...
The aim of this study was to increase understanding the kinetics microparticle distribution and elimination following intranasal application. To do we investigated in-vivo radioactivity instillation scandium-46 labelled styrene-divinyl benzene 7-microm-diameter microspheres. Groups BALB/c mice received 0.250 mg (47.5 kBq) particles suspended in either 50-microL or 10-microL volumes phosphate buffered saline. influenced by volume liquid that used instil microsphere suspension. Comparatively...
ABSTRACT Despite several attempts to develop an effective prophylactic vaccine for HSV-2, all have failed show efficacy in the clinic. The most recent of these failures was GlaxoSmithKline (GSK) subunit based on glycoprotein gD with adjuvant monophosphoryl lipid A (MPL). In a phase 3 clinical trial, this protect from HSV-2 disease, even though good neutralizing antibody responses were elicited. We aimed superior, novel containing either or gB alone combination, together potent CpG...
Abstract Recent accelerated approvals of Chimeric Antigen Receptor T‐cell (CAR‐T) therapies targeting refractory haematological malignancies underscore the potential for this novel technology platform to provide new therapeutic options oncology areas with high unmet medical needs. However, these powerful ‘living drugs’ are markedly different conventional small molecule and biologic on several levels. The highly complex nature varied composition CAR‐T based products still requires...
CD73 is a cell surface 5'nucleotidase (NT5E) and key node in the catabolic process generating immunosuppressive adenosine cancer. Using murine monoclonal antibody surrogate of Oleclumab, we investigated effect inhibition concert with cytotoxic therapies (chemotherapies as well fractionated radiotherapy) PD-L1 blockade. Our results highlight improved survival syngeneic tumor models colorectal cancer (CT26 MC38) sarcoma (MCA205). This therapeutic outcome was part driven by CD8 T-cells,...
Abstract Background: IL-12 is a key mediator of antitumor immune response. In preclinical models, IT mRNA led to IFNγ release and CD8+ T cell-dependent tumor regression potentiated PD-L1 blockade. MEDI1191, lipid nanoparticle-formulated encoding delivered by injection, drives production enhances response with improved tolerability. We hypothesized that combining MEDI1191 blockade would augment immunity in vivo. Here we report updated results from the dose-escalation phase first-in-human...
The prognosis for patients with pancreatic ductal adenocarcinoma (PDAC) remains extremely poor. It has been suggested that the adenosine pathway contributes to ability of PDAC evade immune system and hence, its resistance immuno-oncology therapies (IOT), by generating extracellular (eAdo).